Form 4: BridgeBio Director Sells Shares Under 10b5-1 Plan

BridgeBio Pharma Director Andrea Ellis exercised stock options and sold 17,167 shares for $49.00 each under a pre-arranged Rule 10b5-1 plan.

Summary

• Director Andrea Ellis exercised 17,167 stock options at an exercise price of $16.75 per share.
• Simultaneously, 17,167 shares of common stock were sold at a price of $49.00 per share.
• The transactions were executed on August 5, 2025, as part of a Rule 10b5-1 sales plan adopted on December 30, 2024.
• Following these transactions, Andrea Ellis directly holds 18,589 shares of common stock and 34,334 stock options.
• The stock options vest in three annual installments from June 21, 2024, through June 21, 2026, contingent on continued board service.

Sentiment

Score: 6

Explanation: The transaction is a routine, pre-planned insider sale under a 10b5-1 plan, which is generally viewed neutrally. While it represents a reduction in direct share ownership by a director, the pre-planned nature mitigates negative sentiment. The director also realized a significant profit from the option exercise.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned diversification or liquidity event rather than a reaction to new, undisclosed negative information.
• The director realized a significant profit from the option exercise and sale, with shares sold at $49.00 against an exercise price of $16.75.

Negatives

• A director's sale of shares, even if pre-planned, reduces their direct equity stake in the company.

Risks

• The vesting of remaining stock options is subject to the reporting person's continued service on the Issuer's board of directors.

Future Outlook

The remaining stock options held by Andrea Ellis are scheduled to vest in three annual installments through June 21, 2026, contingent on her continued service on the board of directors.

Industry Context

This Form 4 filing details a routine insider transaction by a director of a biopharmaceutical company. Such transactions are common for executives and directors to manage their personal equity holdings and are often pre-planned through Rule 10b5-1 plans to avoid concerns about insider trading.

Corporate Governance

Related Party Transactions

• The reported transaction involves a director of BridgeBio Pharma, Inc., Andrea Ellis, exercising stock options and selling common stock, which is a transaction by a related party.

Stakeholder Impact

• Shareholders: The sale by a director, even if pre-planned, might be perceived as a slight negative, but the 10b5-1 plan mitigates concerns about opportunistic selling.

Next Steps

• Remaining stock options will continue to vest in annual installments through June 21, 2026, subject to continued board service.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Rule 10b5-1 Plan, Equity Compensation